Motorola Solutions Inc. Stock Falls Monday, Still Outperforms Market

TetraLogic Pharmaceuticals Corp

Change company Symbol lookup

Select an option...

TLOG TetraLogic Pharmaceuticals Corp

JPM-K JPMorgan Chase & Co

KLAC KLA Corp

CNVY Convey Health Solutions Holdings Inc

EBAY eBay Inc

PRLX Parallax Health Sciences Inc

AXS AXIS Capital Holdings Ltd

SPNS Sapiens International Corporation NV

SPCE Virgin Galactic Holdings Inc

BBLG Bone Biologics Corp

Company profile

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Motorola Solutions Inc. Stock Falls Monday, Still Outperforms Market

5:08 pm ET June 13, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Motorola Solutions Inc. (MSI) slipped 3.17% to $202.61 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 3.88% to 3,749.63 and Dow Jones Industrial Average falling 2.79% to 30,516.74. This was the stock's fourth consecutive day of losses. Motorola Solutions Inc. closed $71.04 below its 52-week high ($273.65), which the company reached on December 30th.

The stock underperformed when compared to some of its competitors Monday, as L3Harris Technologies Inc. (LHX) fell 2.99% to $233.25. Trading volume (900,905) eclipsed its 50-day average volume of 875,747.

Data source: Dow Jones Market Data, FactSet. Data compiled June 13, 2022.

(END) Dow Jones Newswires

June 13, 2022 17:08 ET (21:08 GMT)